BELLUS HEALTH INC (BLU) Stock Price, Forecast & Analysis
USA - NASDAQ:BLU - CA07987C2040 - Common Stock
BLU Key Statistics, Chart & Performance
The current stock price of BLU is 14.74 USD. In the past month the price increased by 1.24%. In the past year, price increased by 58.49%.
BLU Latest News, Press Relases and Analysis
BLU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.2 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About BLU
Company Profile
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Company Info
BELLUS HEALTH INC
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7 CA
CEO: Roberto Bellini
Employees: 74
Phone: 14506804500.0
BELLUS HEALTH INC / BLU FAQ
Can you describe the business of BELLUS HEALTH INC?
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Can you provide the latest stock price for BELLUS HEALTH INC?
The current stock price of BLU is 14.74 USD.
What is the dividend status of BELLUS HEALTH INC?
BLU does not pay a dividend.
What is the ChartMill rating of BELLUS HEALTH INC stock?
BLU has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists BLU stock?
BLU stock is listed on the Nasdaq exchange.
What is the next earnings date for BLU stock?
BELLUS HEALTH INC (BLU) will report earnings on 2023-08-08, after the market close.
BLU Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BLU. When comparing the yearly performance of all stocks, BLU is one of the better performing stocks in the market, outperforming 97.91% of all stocks.
BLU Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BLU. No worries on liquidiy or solvency for BLU as it has an excellent financial health rating, but there are worries on the profitability.
BLU Financial Highlights
Over the last trailing twelve months BLU reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BLU Forecast & Estimates
10 analysts have analysed BLU and the average price target is 15.39 USD. This implies a price increase of 4.44% is expected in the next year compared to the current price of 14.74.
For the next year, analysts expect an EPS growth of -27.52% and a revenue growth -35.9% for BLU